GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Carmell Corp (NAS:CTCX) » Definitions » Institutional Ownership

Carmell (Carmell) Institutional Ownership : 0.98% (As of Jun. 07, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Carmell Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Carmell's institutional ownership is 0.98%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Carmell's Insider Ownership is 1.72%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Carmell's Float Percentage Of Total Shares Outstanding is 72.69%.


Carmell Institutional Ownership Historical Data

The historical data trend for Carmell's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carmell Institutional Ownership Chart

Carmell Historical Data

The historical data trend for Carmell can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 0.02 0.72 0.72 0.72 0.86 0.87 0.87 1.05 0.99 0.98

Carmell Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Carmell (Carmell) Business Description

Traded in Other Exchanges
N/A
Address
2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Carmell Corp is a regenerative care company with a focus on using human biomaterials for aesthetic and medical care. Its commercial product is a human amnion allograft that can be used as a structural barrier for wound healing. Carmell's R&D pipeline includes several innovative aesthetic, epithelial and bone products under development.
Executives
David W Anderson director 519 LYNMERE ROAD, BRYN MAWR PA 19010
Kathryn Gregory director 305 THAYER POND ROAD, WILTON CT 06897
Patrick A Sturgeon officer: CFO and Secretary 600 LEXINGTON AVENUE 33 FLOOR, NEW YORK NY 10022
Richard A Upton director 12 MIDDLE STREET, AMHERST NH 03031
Rajiv Shukla director, 10 percent owner, officer: Chief Executive Officer EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
Randolph W Hubbell director, officer: President and CEO C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William R Newlin director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Steven Bariahtaris director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Jaime Garza director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Janet Vargo officer: VP Clinical Services C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Donna Godward officer: Chief Quality Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
James C Hart officer: Chief Medical Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William Woodward director ANTHEM VENTURE PARTNERS, 225 ARIZONA AVENUE, SUITE 200, SANTA MONICA CA 90401
Darlene T Deremer director 200 CENTRAL AVENUE, SUITE 1850, ST. PETERSBURG FL 33701
Ahac Sponsor Iii Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 5TH FLOOR, NEW YORK NY 10036